TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9002334

Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Mega-dose capsule distribution (100,000 IU for 6-12 months; 200,000 IU for 1-5 years)
Number of subjects: 40000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40000
Study: 1618248

Group type: EXPERIMENTAL
Intervention: Oral administration of quinine (500 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous administration of quinine (500 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both oral and intravenous administration of quinine (500 mg)
Number of subjects: 10
Study: 6204486

Group type: EXPERIMENTAL
Intervention: Topical clobetasol-17-propionate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 17
Study: 31227432

Group type: EXPERIMENTAL
Intervention: Abiraterone (1000 mg daily) + Dasatinib (100 mg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Abiraterone (1000 mg daily)
Number of subjects: 26
Study: 30897992

Group type: EXPERIMENTAL
Intervention: In situ measurements of polyp size
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: First in situ measurement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Second in situ measurement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pre-fixation measurement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Detection of ≥20 mm polyps
Number of subjects: 40
Study: 28282396

Group type: EXPERIMENTAL
Intervention: Malaria vaccine (FMP2.1/AS02A)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control (rabies vaccine)
Number of subjects: 400
Study: 26122751

Group type: EXPERIMENTAL
Intervention: Motivational interviewing sessions focused around expectations and planning for the future
Number of subjects: 200
Study: 23348980

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg daily)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 21542741

Group type: EXPERIMENTAL
Intervention: Leukotriene-receptor antagonist (LTRA)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Inhaled glucocorticoid
Number of subjects: 318

Group type: COMPARATOR
Intervention: Long-acting beta(2)-agonist (LABA)
Number of subjects: 318
Study: 19542792

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 or 120 mg/d
Number of subjects: 1332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1332
Study: 16494150

Group type: EXPERIMENTAL
Intervention: Progressive dilational tracheostomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Forceps dilational tracheostomy
Number of subjects: 100
Study: 12527545

Group type: EXPERIMENTAL
Intervention: Monthly maintenance interpersonal psychotherapy (IPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monthly clinical management and pill placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance IPT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive clinical management and pill placebo
Number of subjects: 0
Study: 11132902

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 157

Group type: COMPARATOR
Intervention: Brimonidine 0.2% twice daily
Number of subjects: 157
Study: 9296894

Group type: EXPERIMENTAL
Intervention: Early CT examination at admission (< 72 hrs)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control CT scans (2‐4 weeks later)
Number of subjects: 47
Study: 8291420

Group type: COMPARATOR
Intervention: Intraarticular injections of hyaluronan (placebo control: saline injections)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Oral fluconazole treatment
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Local and systemic amphotericin B, systemic 5‐fluorocytosine and surgical synovectomy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Quantitation of joint cartilage proteoglycan fragments in synovial fluid
Number of subjects: 1
Study: 3549806

Group type: EXPERIMENTAL
Intervention: 2% minoxidil solution
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 3% minoxidil solution
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo (switched to 3% minoxidil after 4 months)
Number of subjects: 153
Study: 29457986

Group type: EXPERIMENTAL
Intervention: Oro-motor stimulation for 5 min twice a day
Number of subjects: 102

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 102
Study: 27553432

Group type: COMPARATOR
Intervention: Olaparib 300 mg bid for 5 days (multiple dosing)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Olaparib 100 mg (single dose)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Olaparib 300 mg (single dose)
Number of subjects: 228
Study: 24941841

Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES) combined with general intravenous anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Total intravenous anesthesia (control group)
Number of subjects: 60
Study: 22515432

Group type: EXPERIMENTAL
Intervention: Intervention supporting the psychological need for autonomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rationale-only condition (not supporting autonomy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Forced-choice condition (not supporting autonomy)
Number of subjects: 0
Study: 20843301

Group type: EXPERIMENTAL
Intervention: Assertive intervention based on a modified version of the international model of assertive community treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard community care
Number of subjects: 60
Study: 18208642

Group type: EXPERIMENTAL
Intervention: Epoetin zeta
Number of subjects: 313

Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 313
Study: 16155276

Group type: EXPERIMENTAL
Intervention: +ISO (58 g protein powder/d containing 83 mg isoflavones/d)
Number of subjects: 150

Group type: COMPARATOR
Intervention: -ISO (ethanol-extracted soy-protein powder containing 3 mg isoflavones)
Number of subjects: 150
Study: 12514575

Group type: EXPERIMENTAL
Intervention: Combined carotid endarterectomy (CEA) and coronary artery bypass grafting (CABG)
Number of subjects: 10561
Study: 10383525

Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: omeprazole 10 mg
Number of subjects: 424

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 424
Study: 8877824

Group type: EXPERIMENTAL
Intervention: Student service
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formal health care service
Number of subjects: 0

Group type: COMPARATOR
Intervention: No service
Number of subjects: 0
Study: 1889971

Group type: EXPERIMENTAL
Intervention: ethinyl oestradiol combined with polyoestradiol phosphate (EE/EP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: estramustine phosphate (EM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: bilateral orchiectomy
Number of subjects: 24
Study: 6794158

Group type: EXPERIMENTAL
Intervention: Samson circuit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Magill (Mapleson A) circuit
Number of subjects: 0
Study: 30618025

Group type: EXPERIMENTAL
Intervention: Microneedling (MN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Neodymium:yttrium–aluminum–perovskite 1340 nm non‐ablative fractional laser (NAFL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both MN and NAFL
Number of subjects: 20

Group type: COMPARATOR
Intervention: NAFL
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MN
Number of subjects: 20
Study: 28912936

Group type: EXPERIMENTAL
Intervention: QSNYL-FEYL combination
Number of subjects: 41

Group type: COMPARATOR
Intervention: QSNYL
Number of subjects: 41
Study: 27488365

Group type: EXPERIMENTAL
Intervention: Morning ingestion of warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Evening ingestion of warfarin (control)
Number of subjects: 0
Study: 25151492

Group type: EXPERIMENTAL
Intervention: Exercise group (EX) - 10min bouts of thrice‐weekly jumping plus capoeira
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Exercise group (EX)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (CON) - usual PE activities
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 151
Study: 18845520

Group type: EXPERIMENTAL
Intervention: Patient Neurotoxicity Questionnaire (PNQ)
Number of subjects: 61
Study: 15110062

Group type: EXPERIMENTAL
Intervention: Prenatal initiation of services (PP+HS)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Postnatal Healthy Steps (HS)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 439
Study: 11371277

Group type: EXPERIMENTAL
Intervention: Pulsatile cardiopulmonary bypass
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group (no pulsatile cardiopulmonary bypass)
Number of subjects: 173
Study: 9142578

Group type: COMPARATOR
Intervention: heated humidifier (control condition)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: heat and moisture exchanger without filtering function (HME)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: combined heat and moisture exchanger and mechanical filter (HMEF)
Number of subjects: 10
Study: 8314201

Group type: EXPERIMENTAL
Intervention: Bio‐Tropin (recombinant GH, Bio‐Technology, Israel) 0.81 IU/kg/week in 3 equally divided doses, administered at 8.00‐10.00 h (M group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Bio‐Tropin (recombinant GH, Bio‐Technology, Israel) 0.81 IU/kg/week in 3 equally divided doses, administered at 14.00‐16.00 h (AN group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Bio‐Tropin (recombinant GH, Bio‐Technology, Israel) 0.81 IU/kg/week in 3 equally divided doses, administered at 19.00‐21.00 h (NT group)
Number of subjects: 34
Study: 3302121

Group type: EXPERIMENTAL
Intervention: Budipine (60 mg daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 11883307

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (for vaginal hysterectomy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Myomectomy m. Martin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 0
Study: 31255482

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 29994806

Group type: EXPERIMENTAL
Intervention: Hybrid coronary revascularization (HCR)
Number of subjects: 0
Study: 27299457

Group type: EXPERIMENTAL
Intervention: SC peginterferon β‐1a 125 mcg every-2-weeks
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: SC peginterferon β‐1a 125 mcg every-4-weeks
Number of subjects: 1512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: SC peginterferon β‐1a
Number of subjects: 1512
Study: 25261549

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting with longer surgical duration (odds ratio per 10-minute increase, 1.05; 95% confidence interval, 1.03-1.07)
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting with endoscopic vein harvesting (odds ratio, 1.41; 95% confidence interval, 1.16-1.71)
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting with poor target artery quality (odds ratio, 1.43; 95% confidence interval, 1.11-1.84)
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: Postoperative use of clopidogrel or ticlopidine (odds ratio, 1.35; 95% confidence interval, 1.07-1.69)
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: Overall patient-level VGF
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: Overall graft-level VGF
Number of subjects: 1828
Study: 22323410

Group type: EXPERIMENTAL
Intervention: Plasma 25-hydroxyvitamin D (highest tertile, median concentration 30.1 ng/mL)
Number of subjects: 2039

Group type: COMPARATOR
Intervention: Placebo group (n = 1,022)
Number of subjects: 2039

Group type: COMPARATOR
Intervention: Intensive lifestyle group (n = 1,017)
Number of subjects: 2039
Study: 20175410

Group type: EXPERIMENTAL
Intervention: sham-CPAP
Number of subjects: 104

Group type: COMPARATOR
Intervention: polysomnographic measures without sham-CPAP
Number of subjects: 104
Study: 17367217

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg + Amoxicillin 1g + Metronidazole 500 mg + Bismuth subcitrate 240 mg twice daily for two weeks (Group A)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg + Amoxicillin 1g + Furazolidone 200 mg twice daily + Bismuth subcitrate 240 mg twice daily for two weeks (Group B)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Furazolidone regimen for the first week followed by Omeprazole + Amoxicillin + Metronidazole + Bismuth subcitrate for the second week (Group C)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison between groups A and C)
Number of subjects: 314
Study: 16202151

Group type: EXPERIMENTAL
Intervention: DMP 1 (current situation within the German-Diabetes-DMP)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: DMP 2 (ideally implemented DMP with additional interventions)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Routine care (without DMP)
Number of subjects: 4000
Study: 12188390

Group type: EXPERIMENTAL
Intervention: 1,400 mg BID of saquinavir soft gel with zidovudine and lamivudine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1,200 mg TID of saquinavir soft gel with zidovudine and lamivudine
Number of subjects: 40
Study: 10525024

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 18

Group type: COMPARATOR
Intervention: Right lateral position
Number of subjects: 18
Study: 7586356

Group type: EXPERIMENTAL
Intervention: Propafenone 300 mg BID
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propafenone 300 mg TID
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2177889

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (2 puffs à 2 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7447172

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-risk group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Common duct exploration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiographic status of the gallbladder
Number of subjects: 0
Study: 31997146

Group type: EXPERIMENTAL
Intervention: Personalized risk information
Number of subjects: 419

Group type: COMPARATOR
Intervention: Generic risk information (control)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Both personalized and generic risk information
Number of subjects: 419
Study: 31522845

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0·2 mg
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0·1 mg
Number of subjects: 225

Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 225

Group type: COMPARATOR
Intervention: Ranibizumab 0·2 mg vs Laser therapy
Number of subjects: 225

Group type: COMPARATOR
Intervention: Ranibizumab 0·1 mg vs Laser therapy
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0·2 mg vs Ranibizumab 0·1 mg
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 225
Study: 28440041

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted catheter-directed thrombolysis (USAT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional catheter-directed thrombolysis (CDT)
Number of subjects: 48
Study: 26554707

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Non-optimal treatment (CT or IPT)
Number of subjects: 134
Study: 23708802

Group type: EXPERIMENTAL
Intervention: Cross-sensory error signal with a 30° rotated hand-cursor distortion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cross-sensory error signal with further increases (up to 70°)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous study with sensorimotor and cross-sensory errors
Number of subjects: 0
Study: 20499362

Group type: EXPERIMENTAL
Intervention: Estrogen treatment in postmenopausal women for 4 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no estrogen treatment) in postmenopausal women (n = 18)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Physiologic testosterone and estrogen replacement in elderly men
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Withdrawal of testosterone or estrogen in elderly men
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Correlation with changes in bone-resorption markers
Number of subjects: 76
Study: 19302912

Group type: EXPERIMENTAL
Intervention: Naproxen sodium/paracetamol 375/300 mg per 15 mL suspension
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Naproxen sodium/paracetamol 275/300 mg tablet
Number of subjects: 52
Study: 17578313

Group type: EXPERIMENTAL
Intervention: Jianpi Qingre Huayu Recipe (JQH)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ranitidine (Control)
Number of subjects: 50
Study: 15114697

Group type: EXPERIMENTAL
Intervention: S-1 administered twice daily at 80, 100 or 120 mg/body/day for 28 days followed by 14 days of rest
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 81
Study: 11263760

Group type: EXPERIMENTAL
Intervention: Symptomatic drugs for Alzheimer's disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictive tools for asymptomatic individuals
Number of subjects: 0
Study: 9713009

Group type: COMPARATOR
Intervention: Thrice daily tobramycin (15 mg/kg/day) combined with ceftazidime (200 mg/kg/day as three intravenous injections)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Once daily tobramycin (15 mg/kg/day) combined with ceftazidime (200 mg/kg/day as three intravenous injections)
Number of subjects: 22
Study: 8790516

Group type: EXPERIMENTAL
Intervention: Annual screening for seven years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mammography detection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BSE education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison centres (non-screening)
Number of subjects: 0
Study: 2928433

Group type: EXPERIMENTAL
Intervention: Diazepam (0.14 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31570034

Group type: EXPERIMENTAL
Intervention: Telemonitored care
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51

Group type: COMPARATOR
Intervention: Phone-call care
Number of subjects: 51
Study: 31734103

Group type: EXPERIMENTAL
Intervention: Cenobamate 100 mg
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Cenobamate 200 mg
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Cenobamate 400 mg
Number of subjects: 437

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study: 30131425

Group type: EXPERIMENTAL
Intervention: High dialysate magnesium (2.0 mEq/L) for 28 days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard dialysate magnesium (1.0 mEq/L)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Comparison of T50 between groups at follow-up
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Comparison of serum magnesium between groups
Number of subjects: 59
Study: 28095807

Group type: EXPERIMENTAL
Intervention: HIV-infected infants on ART
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: HIV-infected infants with virologic suppression and immune recovery at 6 months
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: HIV-infected infants with poor 6-month post-ART responses (lacking viral suppression and immune recovery)
Number of subjects: 165
Study: 26071057

Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Number of subjects: 0

Group type: COMPARATOR
Intervention: levamisole
Number of subjects: 0
Study: 24264551

Group type: EXPERIMENTAL
Intervention: Gabapentin 15 mg.kg‐1 dissolved in 10 ml of saline orally 30 min. before induction of anesthesia
Number of subjects: 46

Group type: COMPARATOR
Intervention: 10 ml of saline (Control)
Number of subjects: 46
Study: 21342757

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (3-month duration)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-intensity exercise training (3-month duration)
Number of subjects: 40
Study: 19108793

Group type: EXPERIMENTAL
Intervention: OXN FDC (10/5 mg, 20/10 mg, 40/20 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oxycodone PR 40 mg + Naloxone PR 20 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: OXN FDC 40/20 mg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Naloxone PR tablet 20 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: OXN, Oxycodone PR, Naloxone PR
Number of subjects: 62
Study: 17017826

Group type: EXPERIMENTAL
Intervention: Olanzapine (10-20 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-160 mg/day)
Number of subjects: 0
Study: 12730793

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 126
Study: 10781448

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% alone, 1.0 mL/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with fentanyl 1 microg/kg
Number of subjects: 60
Study: 9515228

Group type: EXPERIMENTAL
Intervention: JET spacer
Number of subjects: 5

Group type: COMPARATOR
Intervention: pMDI without JET spacer
Number of subjects: 5
Study: 8227450

Group type: EXPERIMENTAL
Intervention: 50 mg meclofenamate sodium bid
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 100 mg meclofenamate sodium bid
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 3817239

Group type: EXPERIMENTAL
Intervention: Dithrocream
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dithranol in Lassar's paste
Number of subjects: 15
Study: 31764461

Group type: EXPERIMENTAL
Intervention: Isometric exercise session (IES) involving large muscle mass: 8 sets × 1 min contraction at 30% maximal voluntary isometric contraction with 2‐min rest interval
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isometric exercise session (IES) involving large muscle mass
Number of subjects: 24
Study: 30998396

Group type: EXPERIMENTAL
Intervention: Genotype-guided antiplatelet therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study: 28069009

Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy for 3 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Room air delivered by a concentrator modified to deliver 21% oxygen (Control)
Number of subjects: 0